Muhammad Khuzzaim Khan

Dr. Muhammad Khuzzaim Khan

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
UZUjala Zubair
Ujala Zubair
MKMuhammad Khuzzaim Khan
Muhammad Khuzzaim Khan
MAMuna Albashari
Muna Albashari
Mental health disorders are an emerging challenge with the progressively increasing usage of social media platforms. Social media use is the second leading cause of disability among psychiatric disorders. A great deal of literature has tried to establish links between social media exposure and mental health diseases. However, there is a need to discuss the current literature that presents crucial perspectives on social media-induced psychiatric disorders to establish a holistic, evidence-based approach for their prevention and treatment. The use of social networks is strongly correlated with the development of anxiety and other psychological problems such as depression, insomnia, stress, decreased subjective happiness, and a sense of mental deprivation. The majority of the cited literature predicts that the likelihood of social media-induced mental health problems is directly proportional to the amount of time spent on these sites, the frequency of usage, and the number of platforms being used. Various possible explanations have been implicated, including a negative impact on self-esteem through unhealthy comparisons, social media burnout, stress, lack of emotional regulation due to social media preoccupation, and development of social anxiety due to decreased real-life social interactions. It has been postulated that increased social media use is driven by preexisting anxiety and is a coping strategy. This era of progressively increasing digitalization, the recent trend of a dramatic shift toward online social life, and the desire to get social attention is expected to take a gruesome toll on the population’s mental health, which therefore warrants more attention to mental health care.

13 March 2023 in Cureus
Verified
Journal Article
Open access
PDF file
NGNitin Ghadge
Nitin Ghadge
AMAndrea Martinez
Andrea Martinez
MBMichelle Bass
Michelle Bass
RWRahul Winayak
Rahul Winayak
MMMidhun Mathew
Midhun Mathew
EKEsma Zeynep Kızılaslan
Esma Zeynep Kızılaslan
Acute intermittent porphyria (AIP) is an autosomal dominant disorder of heme biosynthesis in the liver that is caused by the accumulation of toxic heme metabolites aminolevulinic acid (ALA) and porphobilinogen (PBG) due to a deficiency in the enzyme hydroxymethylbilane synthase (HMBS). The prevalence of AIP is found to commonly affect females of reproductive age (ages 15-50) and people of Northern European descent. The clinical manifestations of AIP include acute and chronic symptoms that can be outlined into three phases: the prodromal phase, the visceral symptom phase, and the neurological phase. Major clinical symptoms involve severe abdominal pain, peripheral neuropathy, autonomic neuropathies, and psychiatric manifestations. Symptoms are often heterogeneous and vague, which can lead to life-threatening signs if not treated and managed appropriately. Whether treating AIP in its acute or chronic form, the cornerstone of treatment consists of the suppression of the production of ALA and PBG. The mainstay of managing acute attacks continues to comprise discontinuing porphyrogenic agents, adequate caloric support, heme treatment, and the treatment of symptoms. In recurrent attacks and chronic management, prevention is key with the consideration of liver transplantation and/or renal transplantation. In recent years, there has been great interest in emerging treatments that focus on a molecular level such as enzyme replacement therapy, ALAS1 gene inhibition, and even liver gene therapy (GT), which has changed the way of traditionally managing this disease and will pave the way for innovative therapies to come.

29 September 2023 in Current Problems in Cardiology
Verified
Journal Article
Closed access
HHHussam Al Hennawi
Hussam Al Hennawi
MZMuhammad Zohaib
Muhammad Zohaib
MKMuhammad Khuzzaim Khan
Muhammad Khuzzaim Khan
FAFasih Ahmed
Fasih Ahmed
OMOmar F. Mathbout
Omar F. Mathbout
UAUsama Ameen Ahmed
Usama Ameen Ahmed

22 April 2024 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
PLPriyanka Mbbs Mohan Lal
Priyanka Mbbs Mohan Lal
MSMuhammad Mbbs Hamza Siddiqui
Muhammad Mbbs Hamza Siddiqui
ASAmna Mbbs Soulat
Amna Mbbs Soulat
AMAnmol Mohan
Anmol Mohan
DTDev Mbbs Tanush
Dev Mbbs Tanush
UTUsha Tejwaney
Usha Tejwaney
Breast cancer (BC), a complex and varied ailment, poses a significant global health burden. MicroRNAs (miRNAs) have emerged as vital regulators in BC progression, with potential implications for diagnosis and treatment. This review aims to synthesize current insights into miRNA dysregulation in BC. MiRNAs, small RNA molecules, govern gene expression post-transcriptionally and are implicated in BC initiation, metastasis, and therapy resistance. Differential expression of specific miRNAs in BC tissues versus normal breast tissue sheds light on underlying molecular mechanisms. MiRNAs also offer promise as diagnostic biomarkers due to their stable nature, accessibility in bodily fluids, and altered expression patterns in early-stage disease, augmenting conventional diagnostic methods. Beyond diagnosis, miRNAs also hold promise as therapeutic targets in BC. By modulating the expression of specific dysregulated miRNAs, it may be possible to restore normal cellular functions and overcome treatment resistance. However, several challenges need to be addressed before miRNA-based therapies can be translated into clinical practice, including the development of efficient delivery systems and rigorous evaluation through preclinical and clinical trials. MiRNAs represent a promising avenue in BC research, offering potential applications in diagnosis, prognosis, and therapeutic interventions. As our understanding of miRNA biology deepens and technology advances, further research and collaborative efforts are needed to fully exploit the diagnostic and therapeutic potential of miRNAs in BC management. Ultimately, the integration of miRNA-based approaches into clinical practice may lead to more personalized and effective strategies for combating this devastating disease.

9 December 2023 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
HHHussam Al Hennawi
Hussam Al Hennawi
MKMuhammad Khuzzaim Khan
Muhammad Khuzzaim Khan
MKMomina Khalid
Momina Khalid
HKHiba Khalid
Hiba Khalid
LFLaveeza Fatima
Laveeza Fatima
BPBehzad Pavri
Behzad Pavri

21 August 2025 in American Journal of Medicine Open
Verified
Journal Article
Open access
BABushra Admani
Bushra Admani
FRFizza Zehra Raza
Fizza Zehra Raza
FSFatima Siddiqui
Fatima Siddiqui
MAMuhammad Talal Ashraf
Muhammad Talal Ashraf
MKMuhammad Khuzzaim Khan
Muhammad Khuzzaim Khan
SLSunita Lakhani
Sunita Lakhani
SGLT2 inhibitors are a new class of antidiabetic drugs that have shown cardiovascular benefits in patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease. However, their effects on fracture risk are unclear and may depend on the type and duration of treatment. This meta-analysis compares the fracture risk of different antidiabetic drugs, including SGLT2 inhibitors, based on data from randomized controlled trials (RCTs). We searched 4 databases for RCTs that reported fracture events in patients with T2DM who received different antidiabetic drugs. We included 117 RCTs that compared 9 types of antidiabetic drugs: SGLT2 inhibitors, DPP-4 inhibitors, α-glucosidase inhibitors, thiazolidinediones, insulin, GLP-1 receptor agonists, meglitinides, biguanides, and sulfonylureas. We used a statistical method called Frequentist meta-analysis to combine data from different studies and compare different treatments. The results showed that SGLT2 inhibitors were the only drug that significantly reduced the fracture risk compared to placebo and other drugs (OR 0.85; 95% CI, 0.74-0.98). The other antidiabetic drugs did not show any significant difference from placebo or from each other. The mechanisms behind the effects of SGLT2 inhibitors on bone health are not well understood and may involve changes in calcium, phosphate, sodium, and arginine vasopressin levels in the body. SGLT2 inhibitors demonstrated a favorable skeletal safety profile among antidiabetic drugs. More long-term studies focused on fracture as a primary outcome are needed to fully understand how SGLT2 inhibitors affect bone health and fracture risk in patients with T2DM.